Fat-soluble vitamin
CCP: Major, life-threatening bleeding in patients with an INR > 1.5, on warfarin therapy, or with vitamin K deficiency
Hypersensitivity to vitamin K (phytonadione) or any component of the formulation
CCP: Major, life-threatening bleeding in patients with an INR > 1.5, on warfarin therapy, or with vitamin K deficiency
CCP: Major, life-threatening bleeding in patients with an INR > 1.5, on warfarin therapy, or with vitamin K deficiency
Promotes liver synthesis of clotting factors (II, VII, IX, X); however, the exact mechanism as to this stimulation is unknown.
Cardiovascular: Chest pain, flushing, hypotension, tachycardia, weak pulse
Central nervous system: Dizziness
Dermatologic: Diaphoresis, eczematous rash, erythema, erythematous rash, pruritic plaques of the skin, urticaria
Gastrointestinal: Dysgeusia
Hepatic: Hyperbilirubinemia
Hypersensitivity: Anaphylactoid reaction, anaphylaxis, hypersensitivity reaction
Local: Injection site reaction (including pain, swelling, tenderness)
Respiratory: Cyanosis, dyspnea
Miscellaneous: Lesion (scleroderma-like)
Fatal hypersensitivity reactions, including anaphylaxis, have occurred with parenteral use; onset may occur during or immediately after intravenous (IV) or intramuscular (IM) administration. Reactions have occurred despite dilution to avoid rapid IV infusion and with the first dose.